Pieris Pharma (PIRS) Tops Q2 EPS by 2c

Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $160.24 million versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance